Telomir Pharmaceuticals Inc

TELO

Latest QuantConomy context for TELO: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

NASDAQ

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for TELO. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for TELO

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
fundamental eps change	very bullish	76	May 14, 12:00 AM	TELO (Q1 2026, diluted eps): EPS grew 90.9% ($-0.33 → $-0.03). [sequential period basis, very bullish signal]
corporate event reg fd disclosure	neutral	70	Jun 15, 12:05 PM	TELO filed 8-K: Regulation FD Disclosure - 1 material event - [strong neutral signal]
corporate event executive change	neutral	75	Jun 8, 09:05 PM	TELO filed 8-K: Director or Officer Changes - 1 material event - [strong neutral signal]

FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.

Market	Exchange	Source	Asset record
TELO	NASDAQ	alpaca	Telomir Pharmaceuticals, Inc. Common Stock
TELO	NASDAQ	alphavantage	Telomir Pharmaceuticals Inc
TELO	NASDAQ	fmp	Telomir Pharmaceuticals, Inc. Common Stock

Buys, last 90d

Sells, last 90d

Rows

Date	Insider	Role	Type	Shares	Price	Value	Filing
May 21, 2026	Whalen Matthew Pratt	Insider	grant	25,000	—	—	4 on EDGAR
May 21, 2026	Del Giudice Matthew Paul	Insider	grant	25,000	—	—	4 on EDGAR
May 21, 2026	MacPherson Edward Clouston	Insider	grant	25,000	—	—	4 on EDGAR
May 21, 2026	Aminov Erez	CEO and Chairman	grant	1,960,170	—	—	4 on EDGAR
Apr 22, 2026	Aminov Erez	CEO and Chairman	other	7,319,710	$1.37	$10,028,003	4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.